国际眼科纵览

• 综述 •    下一篇

TSG-6在眼科疾病中的研究进展

孙高园 王庆平   

  1. 200040上海,复旦大学附属华山医院眼科
  • 收稿日期:2017-05-26 出版日期:2017-08-22 发布日期:2017-09-01
  • 通讯作者: 王庆平,Email:wangqingping7l@163.com E-mail:wangqingping7l@163.com

Recent advances of TSG-6 in ophthalmic diseases

SUN Gao-yuan, WANG Qing-ping   

  1. Department of Ophthalmology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China
  • Received:2017-05-26 Online:2017-08-22 Published:2017-09-01
  • Contact: WANG Qing-ping, Email: wangqingping7l@163.com E-mail:wangqingping7l@163.com

摘要:

肿瘤坏死因子α刺激基因-6(tumor necrosis factor α stimulated gene 6, TSG-6)编码的分泌性蛋白是一种保护性的炎症反应因子,它通过与透明质酸、硫酸软骨素或蛋白多糖结合,介导炎症细胞迁移、黏附,参与免疫调节和细胞外基质重塑,进而发挥炎症调控作用。重组TSG-6蛋白已应用于多种疾病模型的研究,并表现出了广泛而强烈的抗炎作用。最近的研究发现,重组人TSG-6局部应用可减轻多种眼病的炎症反应和病理表现。近几年间充质干细胞在眼科疾病的研究和应用取得了突破性的进展,而TSG-6已被证明是间充质干细胞发挥作用的关键媒介。这提示TSG-6很可能成为眼病治疗的新靶点,有潜在的临床应用价值。

Abstract:

TSG-6 protein is a protective inflammatory factor, which plays the role of anti-inflammatory by binding to hyaluronic acid, chondroitin sulfate, or proteoglycan to mediate inflammatory cell migration and adhesion, and then participate the immune regulation and extracellular matrix remodeling. Recombinant TSG-6 protein has been applied to a variety of disease models, and has shown a broad and strong inhibition of inflammation. Recent studies have found that TSG-6 not only can directly ameliorate the pathologic manifestation of various ophthalmic diseases, but also can act as the media of the stem cells to inhibit inflammatory responses. This suggests that TSG-6 may be a therapeutic target for ophthalmic diseases, with a potential clinical value for clinical application.